Precision Biosciences (DTIL) Operating Leases (2020 - 2026)

Precision Biosciences (DTIL) has 7 years of Operating Leases data on file, last reported at $6.0 million in Q1 2026.

• On a quarterly basis, Operating Leases changed 0.02% year-over-year to $6.0 million in Q1 2026; TTM through Mar 2026 was $6.0 million, a 0.02% change from a year earlier, with the FY2025 full-year figure at $4.9 million, down 23.53% from the prior year.
• Operating Leases for Q1 2026 stood at $6.0 million, up from $4.9 million in the prior quarter.
• Over the last five years, Operating Leases for DTIL reached as high as $7.7 million in Q4 2023 and fell as low as $1.1 million in Q4 2022.
• Historically, Operating Leases has averaged $5.2 million across 5 years, with a median of $5.9 million in 2025.
• Across the five-year window, Operating Leases plunged 78.0% in 2022 and soared 629.27% in 2023, its largest moves.
• Year by year, Operating Leases stood at $1.1 million in 2022, then surged by 629.27% to $7.7 million in 2023, then fell by 17.08% to $6.4 million in 2024, then slipped by 23.53% to $4.9 million in 2025, then rose by 23.48% to $6.0 million in 2026.
• Per Business Quant data, the three most recent Operating Leases figures were $6.0 million in Q1 2026, $4.9 million in Q4 2025, and $6.8 million in Q3 2025.